[go: up one dir, main page]

WO2008056377A3 - Polymorphic forms of rimonabant - Google Patents

Polymorphic forms of rimonabant Download PDF

Info

Publication number
WO2008056377A3
WO2008056377A3 PCT/IN2007/000522 IN2007000522W WO2008056377A3 WO 2008056377 A3 WO2008056377 A3 WO 2008056377A3 IN 2007000522 W IN2007000522 W IN 2007000522W WO 2008056377 A3 WO2008056377 A3 WO 2008056377A3
Authority
WO
WIPO (PCT)
Prior art keywords
rimonabant
polymorphic forms
hydratcd
preparation
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2007/000522
Other languages
French (fr)
Other versions
WO2008056377A2 (en
Inventor
Parind Narendra Dholakia
Mayank Ghanshyambhai Dave
Bipin Pandey
Pankaj Ramanbhai Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of WO2008056377A2 publication Critical patent/WO2008056377A2/en
Publication of WO2008056377A3 publication Critical patent/WO2008056377A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed herein are the novel amorphous hydratcd and crystalline forms of Rimonabant, process(s) for their preparation and pharmaceutical compositions containing it.
PCT/IN2007/000522 2006-11-06 2007-11-05 Polymorphic forms of rimonabant Ceased WO2008056377A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1839/MUM/2006 2006-11-06
IN1839MU2006 2006-11-06
IN1846/MUM/2006 2006-11-07
IN1846MU2006 2006-11-07

Publications (2)

Publication Number Publication Date
WO2008056377A2 WO2008056377A2 (en) 2008-05-15
WO2008056377A3 true WO2008056377A3 (en) 2008-10-30

Family

ID=39322618

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000522 Ceased WO2008056377A2 (en) 2006-11-06 2007-11-05 Polymorphic forms of rimonabant

Country Status (1)

Country Link
WO (1) WO2008056377A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
WO2024092205A1 (en) * 2022-10-27 2024-05-02 The Trustees Of Indiana University Inhibition of ship1 as a therapeutic strategy for the treatment of alzheimer's disease

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656354A1 (en) * 1993-12-02 1995-06-07 Sanofi Substituted N-piperidino 3-pyrazolecarboxamide
WO2003040105A1 (en) * 2001-11-08 2003-05-15 Sanofi-Synthelabo Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same
EP1816125A1 (en) * 2006-02-02 2007-08-08 Ranbaxy Laboratories, Ltd. Novel crystalline forms of an antagonist of CB1 cannabinoid receptor and preparation method thereof
WO2007090949A1 (en) * 2006-02-08 2007-08-16 Sanofi-Aventis Rimonabant monohydrate, process for the preparation thereof and pharmaceutical compositions containing same
WO2007103711A2 (en) * 2006-03-01 2007-09-13 Dr. Reddy's Laboratories Ltd. Polymorphic forms of rimonabant
WO2008026219A2 (en) * 2006-09-01 2008-03-06 Hetero Drugs Limited Novel polymorphs of rimonabant
WO2008035023A1 (en) * 2006-09-19 2008-03-27 Cipla Limited Polymorphs of rimonabant
WO2008064615A2 (en) * 2006-12-01 2008-06-05 Zentiva, A.S. Crystalline and amorphous forms of rimonabant and processes for obtaining them

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656354A1 (en) * 1993-12-02 1995-06-07 Sanofi Substituted N-piperidino 3-pyrazolecarboxamide
WO2003040105A1 (en) * 2001-11-08 2003-05-15 Sanofi-Synthelabo Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same
EP1816125A1 (en) * 2006-02-02 2007-08-08 Ranbaxy Laboratories, Ltd. Novel crystalline forms of an antagonist of CB1 cannabinoid receptor and preparation method thereof
WO2007090949A1 (en) * 2006-02-08 2007-08-16 Sanofi-Aventis Rimonabant monohydrate, process for the preparation thereof and pharmaceutical compositions containing same
WO2007103711A2 (en) * 2006-03-01 2007-09-13 Dr. Reddy's Laboratories Ltd. Polymorphic forms of rimonabant
WO2008026219A2 (en) * 2006-09-01 2008-03-06 Hetero Drugs Limited Novel polymorphs of rimonabant
WO2008035023A1 (en) * 2006-09-19 2008-03-27 Cipla Limited Polymorphs of rimonabant
WO2008064615A2 (en) * 2006-12-01 2008-06-05 Zentiva, A.S. Crystalline and amorphous forms of rimonabant and processes for obtaining them

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLTMAN, S.C.W. ET AL, SYNTHESIS, 1984, pages 150 - 152, XP002491304 *
HANCOCK B C ET AL: "What is the true solubility advantage for amorphous pharmaceuticals?", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 17, no. 4, 1 April 2000 (2000-04-01), pages 397 - 404, XP009086748, ISSN: 0724-8741 *
KOTAGIRI V.K. ET AL, ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 11, 2007, pages 910 - 912, XP002491303 *

Also Published As

Publication number Publication date
WO2008056377A2 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
WO2007136510A3 (en) Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha
WO2008021342A3 (en) Amorphous and crystalline forms of 9-hydroxy-risperidone ( paliperidone )
WO2008005877A3 (en) Inhibitors of c-kit and uses thereof
MX2009012561A (en) Stevioside polymorphic and amorphous forms, methods for their formulation, and uses.
WO2008057291A3 (en) Crystalline and amorphous imatinib base, imatinib mesylate- and processes for preparation thereof
WO2009006590A3 (en) Docetaxel process and polymorphs
WO2008049116A3 (en) Substituted indoles
WO2008066935A3 (en) Crystalline forms of tigecycline and processes for preparation thereof
PL1752443T3 (en) New crystalline form V of agometaline, the process for its preparation and the pharmaceutical compositions containing it
WO2010062715A3 (en) Polymorphs of dasatinib and process for preparation thereof
LT2210872T (en) New crystalline form iii of agometalin, the process for its preparation and pharmaceutical compositions containing it
WO2008083130A3 (en) Amorphous and crystalline form a of carvedilol phosphate
WO2008088779A3 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
WO2007044950A3 (en) Crystalline forms of docetaxel and processes for their preparation
WO2007098273A3 (en) Novel crystalline forms of armodafinil and preparation thereof
WO2008137134A3 (en) Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
WO2007010555A3 (en) Novel crystalline forms of moxifloxacin hydrochloride and process for preparation thereof
WO2007148102A3 (en) Crystalline duloxetine hydrochloride
WO2007125521A3 (en) Polymorphic form of zoledronic acid and processes for their preparation
WO2010039885A3 (en) Crystalline forms of dexlansoprazole
WO2008035360A3 (en) Novel crystalline forms of candesartan cilexetil, candesartan, tritylated candesartan and tritylated candesartan cilexetil
WO2007081909A3 (en) Forms of dolasetron mesylate and processes for their preparation
WO2008056377A3 (en) Polymorphic forms of rimonabant
WO2009007747A3 (en) Hydantoin derivatives used as mmp12 inhibitors
MX2010003056A (en) Valomaciclovir polymorphs.

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07870518

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)